Latest Revenue Guidance News

Etherstack has reported a record-breaking 70% revenue increase in FY25, driven by major contracts and strong cashflow, and is poised for further robust growth in FY26.

Bioxyne Limited has delivered a record-breaking second quarter in FY2026, posting $17.2 million in revenue and expanding its footprint into key international markets. The company’s growth is underpinned by new contracts, innovative psychedelics products, and strategic government funding.

Change Financial Limited has reported a record revenue quarter driven by its Vertexon platform growth and new client wins, prompting an upgrade to its FY26 financial guidance.

FINEOS Corporation Holdings PLC reports a robust €27.8 million cash balance at the end of 2025, maintaining its FY25 revenue guidance despite seasonal cash flow dips and currency fluctuations.

Following its December 2025 ASX debut and a successful IPO, Saluda Medical reports robust global revenue growth and expands its US sales force, prompting an upward revision of its FY26 revenue guidance.

TZ Limited reported a quarterly cash outflow of A$790,000 impacted by payment timing but maintains full-year revenue guidance amid strategic advances in smart locker and data centre security sectors.

Electro Optic Systems (EOS) reports a record $459 million contract backlog, major new defence contracts including a $120 million laser weapon deal, and a strategic acquisition to boost counter-drone capabilities.

Pureprofile has reported record first-half FY26 results, driven by strong international expansion and AI-powered platform growth, prompting an upgrade to its full-year revenue guidance.

Pureprofile Limited has upgraded its FY26 revenue guidance after a record first half, driven by strong international growth and a booming platform business. The Rest of World segment now outpaces ANZ, signalling a major shift in the company’s geographic footprint.

Change Financial has reported a robust first half of FY26, with revenue and EBITDA surpassing expectations, prompting an upgraded full-year guidance and signalling a key milestone in cash flow positivity.

Cogstate Ltd has reported a remarkable 105% surge in clinical trial sales contracts for the first half of 2026, surpassing revenue guidance and signalling a more diversified and resilient business model.

Telix Pharmaceuticals has met its upgraded FY 2025 revenue guidance with US$804 million, driven by strong growth in its Precision Medicine segment and the successful US launch of Gozellix. The company also advanced multiple clinical trials and announced a strategic collaboration with Varian to combine radiopharmaceuticals with radiation therapy.